natgillin/translations-raw huggingface dataset:
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg azilsartan medoxomil (as potassium) 
Ena tableta vsebuje 80 mg medoksomilazilsartanata (v obliki kalijeve soli).
EXPIRY DATE 
Študija VA
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg azilsartan medoxomil (as potassium) 
Ena tableta vsebuje 40 mg medoksomilazilsartanata (v obliki kalijeve soli).
The incidence of adverse reactions with Ipreziv was not affected by gender, age, or race. 
Spol, starost ali rasa niso vplivali na pogostnost neželenih učinkov zdravila Ipreziv.
Common side effects affecting less than 1 in 10 people: - Dizziness - Diarrhoea - Increased blood creatine phosphokinase (an indicator of muscle damage). 
- omotica - driska - zvišanje vrednosti kreatin-fosfokinaze (pokazatelj poškodbe mišic).
Before you take, or whilst you are taking Ipreziv, tell your doctor if you: - have kidney problems - are on dialysis or had a recent kidney transplant 
- ste na dializi ali vam je bila pred kratkim presajena ledvica, - imate hudo bolezen jeter,
Hepatic impairment 
- mišični krči
- For patients who recently have lost body fluids e.g. through vomiting or diarrhoea, or by taking water tablets, your doctor may recommend a lower starting dose of 20 mg once a day. 
Zdravnik lahko ta odmerek glede na reakcijo vašega krvnega tlaka poveča na največ 80 mg enkrat na dan. - Pri starejših starostnikih (75 let in več) lahko zdravnik priporoči nižji začetni odmerek 20 mg - Če imate blago ali zmerno jetrno bolezen, vam bo zdravnik morda priporočil nižji začetni - Če ste pred kratkim izgubili več telesnih tekočin, npr. zaradi bruhanja, driske ali zaradi zdravil za odvajanje vode, vam bo zdravnik morda priporočil nižji začetni odmerek 20 mg enkrat na - Če imate drugo sočasno bolezen kot npr. hudo ledvično bolezen ali srčno popuščanje, se bo zdravnik odločil za najbolj primeren začetni odmerek.
The main measure of effectiveness was the increase in height of patients after one year of treatment. 
Glavno merilo učinkovitosti je bilo povečanje telesne višine bolnikov po enem letu zdravljenja.
However, these antibodies do not seem to have an effect on the way the medicine works. 
Vendar se zdi, da ta protitelesa ne vplivajo na način delovanja zdravila.
It promotes growth during childhood and adolescence, and also affects the way the body handles proteins, fat and carbohydrates. 
Žleza spodbuja rast v otroštvu in mladostništvu ter vpliva na način, kako telo presnavlja beljakovine, maščobe in ogljikove hidrate.
In addition, the company that markets Somatropin Biopartners will provide further long-term data on the effectiveness and safety of the medicine. 
Poleg tega bo družba, ki trži zdravilo Somatropin Biopartners, zagotovila nadaljnje dolgoročne podatke o učinkovitosti in varnosti zdravila.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Somatropin Biopartners' benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) agencije je zaključil, da so koristi zdravila Somatropin Biopartners večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The full EPAR for Somatropin Biopartners can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Somatropin Biopartners je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Somatropin Biopartners. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Somatropin Biopartners.
The European Commission granted a marketing authorisation valid throughout the European Union for Somatropin Biopartners on 05.08.2013. 
Evropska komisija je dovoljenje za promet z zdravilom Somatropin Biopartners, veljavno po vsej Evropski uniji, odobrila 05.08.2013.
It is used to treat children aged 2 to 18 years who are failing to grow normally because they do not have enough growth hormone. 
Uporablja se za zdravljenje otrok, starih od 2 do 18 let, ki zaradi pomanjkanja rastnega hormona ne rastejo ustrezno.
Somatropin Biopartners is injected under the skin once a week. 
Zdravilo Somatropin Biopartners se injicira pod kožo enkrat na teden.
In adults, the most common side effects (which may affect more than 1 in 10 people) are swelling, mild hyperglycaemia (high blood sugar levels) and headache. 
Pri odraslih so najpogostejši neželeni učinki (ki se lahko pojavijo pri več kot 1 od 10 oseb) otekanje, blaga hiperglikemija (visoke ravni sladkorja v krvi) in glavobol.
In adults, the recommended dose is 2 mg injected once a week, except for female patients also taking oral oestrogen who should receive 3 mg once a week. 
Pri odraslih je priporočen odmerek 2 mg, ki se injicira enkrat na teden, razen pri ženskih bolnicah, ki sočasno jemljejo peroralni estrogen in morajo prejeti 3 mg enkrat na teden.
The dose may need to be adjusted, depending on the patient's response to treatment and the side effects the patient experiences. 
Odmerek bo morda treba prilagoditi glede na bolnikov odziv na zdravljenje in pojavljajoče se neželene učinke.
In children, the recommended dose is 0.5 mg per kilogram body weight, injected once a week. 
Pri otrocih je priporočen odmerek 0,5 mg na kilogram telesne mase, ki se injicira enkrat na teden.
Somatropin Biopartners is a medicine that contains human growth hormone (also known as somatropin). 
Somatropin Biopartners je zdravilo, ki vsebuje človeški rastni hormon (znan tudi kot somatropin).
Somatropin Biopartners must not be used in patients with an active tumour or an acute lifethreatening illness. 
Zdravilo Somatropin Biopartners se ne sme uporabljati pri bolnikih z aktivnim tumorjem ali z akutno življenjsko nevarno boleznijo.
The study showed that Somatropin Biopartners was as effective as Genotropin at promoting growth: children receiving Somatropin Biopartners grew around 11.7 cm in one year, compared with 12.0 cm in children receiving Genotropin. 
Študija je pokazala, da je bilo zdravilo Somatropin Biopartners pri spodbujanju rasti enako učinkovito kot Genotropin: otroci, ki so prejemali zdravilo Somatropin Biopartners, so v enem letu zrasli za približno 11,7 cm, otroci, ki so prejemali zdravilo Genotropin, pa za 12,0 cm.
What measures are being taken to ensure the safe and effective use of Somatropin Biopartners? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Somatropin Biopartners?
A risk management plan has been developed to ensure that Somatropin Biopartners is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Somatropin Biopartners je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Somatropin Biopartners, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Somatropin Biopartners vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The patient or caregiver can inject Somatropin Biopartners themselves, after training by a doctor or a nurse. 
Bolnik ali njegov negovalec lahko zdravilo Somatropin Biopartners injicira sam, potem ko ga o tem pouči zdravnik ali medicinska sestra.
It is also used in adults with a lack of growth hormone who may have either had growth hormone deficiency as children or developed it later during adulthood. 
Uporablja se tudi pri odraslih s pomanjkanjem rastnega hormona, ki se je pojavilo v otroštvu ali pozneje v odrasli dobi.
In adults who lack growth hormone, Somatropin Biopartners has a modest effect in decreasing body fat. 
Pri odraslih s pomanjkanjem rastnega hormona ima zdravilo Somatropin Biopartners zmeren učinek na zmanjšanje telesne maščobe.
Adults treated with Somatropin Biopartners had an average reduction of body fat of 1 kg while body fat in those treated with placebo increased by 0.5 kg. 
Pri odraslih, ki so prejemali zdravilo Somatropin Biopartners, so zabeležili povprečno zmanjšanje telesne maščobe za 1 kg, medtem ko so pri odraslih, ki so prejemali placebo, zabeležili povečanje za 0,5 kg.
The study compared Somatropin Biopartners given once a week with another somatropin-containing medicine called Genotropin given once a day. 
V študiji so primerjali zdravilo Somatropin Biopartners, dano enkrat na teden, z drugim zdravilom, ki vsebuje somatropin in se imenuje Genotropin, danim enkrat na dan.
In children, the most common side effects with Somatropin Biopartners (which may affect more than 1 in 10 people) are injection site swelling and development of antibodies (proteins that are produced in response to Somatropin Biopartners). 
Pri otrocih so najpogostejši neželeni učinki zdravila Somatropin Biopartners (ki se lahko pojavijo pri več kot 1 od 10 oseb) oteklina na mestu injiciranja in razvoj protiteles (beljakovin, ki se tvorijo kot odziv na zdravilo Somatropin Biopartners).
It is produced by a method known as ‘recombinant DNA technology': the hormone is made by yeast cells into which a gene (DNA) has been introduced that makes them able to produce it. Somatropin Biopartners replaces the natural hormone. 
Proizvaja se z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri hormon izdelajo celice kvasovk, v katere so vstavili gen (DNK), s pomočjo katerega ga celice lahko tvorijo.
For more information about treatment with Somatropin Biopartners, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Somatropin Biopartners preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This study compared Somatropin Biopartners with placebo (a dummy treatment) and measured the decrease in body fat (which is normally high in adults with growth hormone deficiency) after 6 months of treatment. 
V študiji so zdravilo Somatropin Biopartners primerjali s placebom (zdravilom brez zdravilne učinkovine) in merili zmanjšanje telesne maščobe (ki je običajno visoka pri odraslih s pomanjkanjem rastnega hormona) po 6 mesecih zdravljenja.
Regarding its safety, the side effects reported with Somatropin Biopartners were similar to those of other daily somatropin medicines, with the exception of increased injection site reactions in children, which should be balanced against the convenience of weekly injections. 
V zvezi z njegovo varnostjo so bili neželeni učinki, o katerih so poročali pri zdravilu Somatropin Biopartners, podobni učinkom drugih zdravil, ki vsebujejo somatropin in se dajejo dnevno, razen povečanih reakcij na mestu injiciranja pri otrocih, kar je treba odtehtati s priročnostjo tedenskega injiciranja.
The active substance in Somatropin Biopartners, somatropin, is identical to the human growth hormone. 
Zdravilna učinkovina v zdravilu Somatropin Biopartners, somatropin, je identična človeškemu rastnemu hormonu.
Somatropin Biopartners is available as a powder and solvent which are made into a suspension for injection. 
Zdravilo Somatropin Biopartners je na voljo v obliki praška in vehikla za pripravo suspenzije za injiciranje.
The Committee concluded that Somatropin Biopartners is as effective in children who fail to grow normally as other somatropin-containing treatments given daily. 
Odbor je zaključil, da je zdravilo Somatropin Biopartners pri otrocih, ki ne rastejo ustrezno, enako učinkovito kot druga zdravila, ki vsebujejo somatropin in se dajejo dnevno.
For practical information about using Somatropin Biopartners, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Somatropin Biopartners naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Somatropin Biopartners has also been studied in one main study involving 151 adults with growth hormone deficiency. 
Zdravilo Somatropin Biopartners so preučevali tudi v eni glavni študiji, v katero je bilo vključenih 151 odraslih s pomanjkanjem rastnega hormona.
Other information about Somatropin Biopartners 
Druge informacije o zdravilu Somatropin Biopartners
Somatropin Biopartners has been studied in one main study involving 180 children with a lack of growth hormone. 
Zdravilo Somatropin Biopartners so preučevali v eni glavni študiji, v katero je bilo vključenih 180 otrok s pomanjkanjem rastnega hormona.
What is Somatropin Biopartners and what is it used for? 
Kaj je zdravilo Somatropin Biopartners in za kaj se uporablja?
For the full list of all side effects reported with Somatropin Biopartners, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Somatropin Biopartners, glejte navodilo za uporabo.
Treatment with Somatropin Biopartners should be started and monitored by a doctor experienced in diagnosing and treating patients with growth hormone deficiency. 
Zdravljenje z zdravilom Somatropin Biopartners lahko uvede in spremlja le zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolnikov s pomanjkanjem rastnega hormona.
Growth hormone is a substance secreted by the pituitary gland (a gland located at the base of the brain). 
Rastni hormon je snov, ki jo izloča hipofiza (žleza, ki se nahaja na možganskem dnu).
What are the risks associated with Somatropin Biopartners? 
Kakšna tveganja so povezana z zdravilom Somatropin Biopartners?
What benefits of Somatropin Biopartners have been shown in studies? 
Kakšne koristi je zdravilo Somatropin Biopartners izkazalo v študijah?
Why is Somatropin Biopartners approved? 
Zakaj je bilo zdravilo Somatropin Biopartners odobreno?
How is Somatropin Biopartners used? 
Kako se zdravilo Somatropin Biopartners uporablja?
It is not intended to provide practical advice on how to use Somatropin Biopartners. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How does Somatropin Biopartners work? 
Kako zdravilo Somatropin Biopartners deluje?
Your doctor will decide if this 
Vaš zdravnik bo presodil, ali je to
Neither of these findings is of clinical relevance. 
Nobena od teh ugotovitev ni klinično pomembna.
Discard open tubes 7 days after opening, even if they are not empty. 
Tube zavrzite 7 dni po prvem odprtju, tudi če še niso prazne.
Re-evaluation of treatment 
Ponovna ocena zdravljenja
Patients aged from 2 months to 24 months 
Bolniki v starosti od 2 do 24 mesecev
Confidence interval was not adjusted for multiplicity. 
Interval zaupanja ni bil prilagojen za raznolikost.
CI: confidence interval. 
IZ: interval zaupanja.
It may harm them, 
površine;
Hypersensitivity, including angioedema 
Preobčutljivost, vključno z angioedemom
If the patient is a child less than two years old it is especially important that you tell your doctor about any other medicines that the child is being given, including medicines bought without a prescription. 
Če je bolnik otrok, mlajši od dveh let, je še posebej pomembno, da zdravniku poveste za vsa druga zdravila, ki jih otrok dobiva, tudi za tista, ki so bila kupljena brez recepta.
Currently available data are described in section 5.2, but no recommendation on a 
Podatki, ki so trenutno na voljo, so opisani v poglavju 5.2, a priporočil za odmerjanje ni
They should not be kept for future use. 
Ne smete jih shraniti za poznejšo uporabo.
Consideration should be given to official guidance on the appropriate use of antibacterial medicinal 
Upoštevati je treba uradne smernice za ustrezno uporabo protibakterijskih zdravil.
Tell your doctor if you are using, have recently used or might use any other medicines. 
Obvestite svojega zdravnika, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katerokoli drugo zdravilo.
95% Exact CI 
95% natančen IZ
See also section 4 of this leaflet. 
Glejte tudi poglavje 4 tega navodila.
In patients aged less than 18 years the total surface area treated should be no more than 2% of the body surface area. 
Pri bolnikih, ki so mlajši od 18 let, celotna zdravljena površina ne sme preseči 2 % telesne površine.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali v 60 dneh po doseženem pomembnem mejniku (farmakovigilančnem ali povezanem z zmanjševanjem tveganja).
It must not be put in the eyes, on the mouth or lips, inside the nose or inside the female genital area. 
Ne smete ga vnašati v oči, usta ali na ustnice, v notranjost nosu ali ženskih spolovil.
Do not use this medicine after the expiry date which is stated on the carton after ‘EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake ‘EXP'.
Exact CI is calculated using the F-distribution method. 
Natančen IZ je izračunan z metodo F-porazdelitve.
Date of first authorisation: 24 May 2007 Date of latest renewal: 20 April 2012 
Datum zadnjega podaljšanja: 20. april 2012
Adults (aged 18-65 years), adolescents (aged 12-17 years), infants and children (aged from nine 
Odrasli (stari od 18 do 65 let), mladostniki (stari od 12 do 17 let), dojenčki in otroci (stari od devet
Carton of 12 sachets. 
Škatla z 12 vrečicami.
If you are allergic to retapamulin or any of the other ingredients of this medicine (listed in section 6). 
Če ste alergični na retapamulin ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
However, due to the low systemic plasma levels that have been observed, no safety problems are foreseen. 
Zaradi majhnih sistemskih plazemskih vrednosti, ki so bile opažene, težav z varnostjo ne pričakujemo.
In vitro, three mechanisms have been identified which reduce susceptibility to retapamulin. 
In vitro so odkrili tri mehanizme, ki zmanjšujejo občutljivost za retapamulin.
Short term treatment of the following superficial skin infections in adults, adolescents, infants and children (aged from nine months) (see section 5.1): 
Kratkotrajno zdravljenje naslednjih povrhnjih okužb kože pri odraslih, mladostnikih, dojenčkih in otrocih (od devetega meseca starosti naprej) (glejte poglavje 5.1):
Other medicines and Altargo 
Druga zdravila in zdravilo Altargo
4.7 Effects on ability to drive and use machines Altargo has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Altargo nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Any remaining ointment at the end of treatment should be discarded. 
Mazilo, ki ostane po koncu zdravljenja, je treba zavreči.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. 
Redno posodobljena poročila o varnosti zdravila (PSUR) Imetnik dovoljenja za promet z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem
Patients not showing a clinical response within two to three days should be re-evaluated and alternative therapy should be considered (see section 4.4). 
Bolnike, pri katerih v dveh do treh dneh ni kliničnega izboljšanja, je treba ponovno pregledati in po presoji uvesti alternativno zdravljenje (glejte poglavje 4.4).
If super-infection with a non-susceptible organism is suspected, treatment should be guided by clinical and microbiological assessments. 
V primeru suma na superinfekcijo z neobčutljivim organizmom je treba zdravljenje usmerjati glede na klinične in mikrobiološke izvide.
$: the response rate for MRSA due to PVL+ MRSA was 8/13 (62%) 
: delež odziva za MRSA zaradi PVL+ MRSA je bil 8/13 (62 %)
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. 
Če ste noseči ali dojite, menite, da ste noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali s farmacevtom, preden uporabite to zdravilo.
Minimal systemic exposure is observed in adults, therefore exposure of the breast-feeding infant is likely to be negligible. 
Pri odraslih je bila opažena minimalna sistemska izpostavljenost, zato je verjetnost za izpostavljenost dojenega otroka malenkostna.
Wash your hands before and after applying the ointment. 
Pred in po nanosu mazila si umijte roke.
If you notice any worsening of the infection or develop increased redness, irritation or other signs and symptoms at the site of application you should stop using Altargo and tell your doctor. 
Če opazite kakršnokoli poslabšanje okužbe ali pojav močnejše rdečine, draženja ali druge znake in simptome na mestu nanosa , morate zdravilo Altargo prenehati uporabljati in o tem obvestiti svojega zdravnika.
• Infected lesions that exceed 10 cm in length or a total surface area >100 cm2. 
• okužene spremembe, daljše od 10 cm ali s skupno površino > 100 cm2.
Frequency, type and severity of adverse reactions in the paediatric population are the same as in adults. 
Pediatrična populacija Pogostnost, vrsta in izrazitost neželenih učinkov v pediatrični populaciji so enake kot pri odraslih.
The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. 
Prevalenca pridobljene odpornosti določenih vrst se lahko razlikuje tako glede na geografsko področje kot čas, zato je najprimernejša uporaba lokalnih podatkov o odpornosti, še posebej pri zdravljenju hudih okužb.
The following convention has been used for the classification of frequency: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1000 to <1/100), rare (>1/10,000 to <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available 
Pogostnost je navedena v skladu z naslednjim dogovorom: Zelo pogosti (> 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (> 1/10.000
* Activity has been satisfactorily demonstrated in clinical studies 
* v kliničnih študijah je bila učinkovitost zadovoljiva.
Pharmacotherapeutic group: Antibiotics and chemotherapeutics for dermatological use, Antibiotics for 
Farmakoterapevtska skupina: antibiotiki in kemoterapevtiki za uporabo v dermatologiji, antibiotiki za lokalno zdravljenje.
If you accidentally use Altargo inside your nose you could have a nose bleed. 
Če zdravilo Altargo pomotoma uporabite v nosu, se vam lahko pojavi krvavitev iz nosu.
If you stop using Altargo too soon, the bacteria may start to grow again and your infection may come back. 
Če ste prenehali uporabljati zdravilo Altargo Če zdravilo Altargo prenehate uporabljati prezgodaj, lahko bakterije znova začnejo rasti in okužba se lahko ponovi.
Abscesses 
Abscesi
In the event of a sensitisation or severe local irritation from the use of retapamulin ointment, treatment should be discontinued, the ointment carefully wiped off, and appropriate alternative therapy for the 
V primeru pojava preobčutljivosti ali hudega lokalnega draženja zaradi uporabe retapamulina v obliki mazila je treba zdravljenje prekiniti, mazilo previdno obrisati in uvesti primerno alternativno